1234798-76-5

Upstream product

• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 1147550-11-5 ammonium thiocyanate 
• 75-36-5 acetyl chloride 

Downstream Products

• 1186620-63-2 methyl 4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzoate 
• 1234798-38-9 N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-benzamide 
• 1234798-39-0 N-(5-(1H-imidazol-1-yl)-3-(trifluoromethyl)-phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-benzamide 
• 1234798-62-9 4-methyl-N-(3-(3-methyl-1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1234798-72-1 4-methyl-N-(3-(1-methyl-1H-pyrazol-4-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1290090-09-3 4-methyl-N-(3-(1-methyl-1H-1,2,3-triazol-4-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1234798-48-1 4-methyl-N-(3-methyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1234798-71-0 N-(3-isopropyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1234798-70-9 N-(3-tert-butyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)benzamide 
• 1290090-12-8 C₃₆H₃₆N₆OS 
• 1234798-64-1 N-(3-chloro-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)benzamide 
• 1186620-64-3 4-methyl-3-[4-(pyridin-3-yl)thiazol-2-ylamino]benzoic acid 

Relevant academic research and scientific papers

A 2-amino-thiazole compounds (by machine translation)

The present invention relates to the technical field of pharmaceutical chemistry, particularly relates to a 2-amino thiazole compound or its pharmaceutically acceptable salts, its preparation method, and pharmaceutical compositions containing such compounds and its application in the preparation of antineoplastic. (by machine translation)

Hybrid compounds as new Bcr/Abl inhibitors

A series of 2,4-disubstituted thiazole derivatives were designed and synthesized as new Bcr/Abl inhibitors by hybriding the structural moieties from FDA approved imatinib, nilotinib and dasatinib. The new inhibitors strongly suppressed the activity of Bcr/Abl kinase and potently inhibited the proliferation of K562 and KU812 leukemia cancer cells. Compound 4i displayed comparable potency with that of nilotinib in both biochemical kinase assay and cancer cell growth inhibition assay. These inhibitors might serve as lead compounds for further developing new anticancer drugs.